https://www.selleckchem.com/pr....oducts/plerixafor-8h
Patients with heterozygous FANCA gene mutations have poorer outcomes.Background Osteosarcoma (OSA), the most common primary bone malignancy in children and adolescents, is prone to metastases and unfavorable prognosis. Owing to its strong genomic heterogeneity, traditional chemotherapy, or targeted immunotherapy has not effectively improved the related overall survival for decades. Since the landscape of the OSA tumor immune microenvironment is scarcely known, despite it playing a crucial role in predicting clinical outc
Like
Comment
Share
